|
|
|
| Effects of Edaravone on Inflammatory Factors and Protein Expression of p38MAPK, p42MAPK and p44MAPK in Cerebral Ischemic Area of Ischemic Stroke Rat Model |
| WANG Xiao-yu, LANG Gui-yan, LI Jin-wei,et al |
| Neurology of Department ,Liaoyang Central Hospital , Liaoyang, Liaoning, 111000 China |
|
|
|
|
Abstract 【Objective】To investigate the effects of edaravone on the expression of inflammatory factors TNF-alpha, IL-6p, p38MAPK, p42MAPK and p44MAPK in cerebral ischemia of ischemic stroke (CIS) rat model.【Methods】 Eighty rats were randomly divided into saline group (40 rats) and edaravone group (40 rats). The edaravone group was intraperitoneally injected with 5 mg / (kg d) edaravone for one week. The saline group was intraperitoneally injected with the same amount of saline. One week after administration, the edaravone group and the saline group were randomly divided into edaravone sham operation group (20 rats), edaravone model group (20 rats), saline sham operation group (20 rats) and saline model group (20 rats). CIS rat model was established by thread embolization. Inflammatory factors TNF-alpha and IL-6 were detected by ELISA. Western blot was used to detect p38MAPK, p42MAPK and p44MAPK proteins in cerebral ischemic area of rats.【Results】The expression levels of TNF-alpha, IL-6 and p38MAPK protein in cerebral ischemic tissue of rats in the saline model group and the edaravone model group were significantly higher than those in the saline sham operation group and the edaravone sham operation group, and the expression levels of TNF-alpha, IL-6 and p38MAPK protein in cerebral ischemic tissue of rats in the saline model group were significantly higher than those in the edaravone model group (P<0.05). However, there was no significant difference in the protein expression levels of p42MAPK and p44MAPK between the groups (P>0.05).【Conclusion】 Edaravone can inhibit the inflammatory response in cerebral ischemic area of CIS rats, which may inhibit the inflammatory response in ischemic area through p38MAPK pathway.
|
|
Received: 17 October 2018
|
|
|
|
|
|
[1] Thorvaldsen P. Stroke trends in the WHO MONICA project[J].Stroke,1997, 28(3): 500-506.
[2] Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia[J].Pharmacol Biochem Behav,2007, 87(1): 179-197.
[3] Suda S.Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging[J].Neurol Med Chir (Tokyo),2007, 47(5): 197-201.
[4] Bederson JB, Pitts LH , Tsuji M,et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination[J].Stroke,1986,17(3), 472-476.
[5] Zhou G, Li MH, Tudor G, et al. Remote ischemic conditioning in cerebral diseases and neurointerventional procedures: recent research progress[J].Front Neurol,2018, 9: 339.
[6] Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury[J].CNS Drug Rev,2006, 12(1): 9-20.
[7] Gairolla J, Kler R, Modi M, et al. Leptin and adiponectin: pathophysiological role and possible therapeutic target of inflammation in ischemic stroke[J].Rev Neurosci,2017, 28(3): 295-306.
[8] Menon R, Papaconstantinou J. p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes[J].Expert Opin Ther Targets,2016, 20(12): 1397-1412.
|
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(4): 740-741. |
|
|
|
|
2019, Vol. 36 
